Long-acting selective beta2 agonist.

Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Norctornal asthma in patients requiring long-term regular bronchodilator therapy
Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma in patients who regularly use an inhaled corticosteroid
By inhalation of powder:
• Child 6-11 years: 12 mcg twice daily should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily.

By inhalation of aerosol:
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily, dose may be increased in more severe airway obstruction; increased to 24 mcg twice daily.

COPD
By inhalation of powder
• Adult: 12 mcg twice daily

By inhalation of aerosol
• Adult: 12 mcg twice daily (maximum per dose 24 mcg). If required, additional doses up to a maximum of 48 mcg per day can be taken.

Long-acting selective beta2 agonist.

Reversible airways obstruction in patients requiring long-term regular bronchodilator therapy
Norctornal asthma in patients requiring long-term regular bronchodilator therapy
Prophylaxis of exercise-induced bronchospasm in patients requiring long-term regular bronchodilator therapy
Chronic asthma in patients who regularly use an inhaled corticosteroid
By inhalation of powder:
• Child 6-11 years: 12 mcg twice daily should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily.

By inhalation of aerosol:
• Child 12-17 years: 12 mcg twice daily. Dose may be increased in more severe airway obstruction to 24 mcg twice daily, which should be sufficient for the majority of children, particularly for younger age-groups. Higher doses should be used rarely, and only when control is not maintained on the lower dose.
• Adult: 12 mcg twice daily, dose may be increased in more severe airway obstruction; increased to 24 mcg twice daily.

COPD
By inhalation of powder
• Adult: 12 mcg twice daily

By inhalation of aerosol
• Adult: 12 mcg twice daily (maximum per dose 24 mcg). If required, additional doses up to a maximum of 48 mcg per day can be taken.

Long acting muscarinic antagonist, long-acting beta 2 agonist and inhaled corticosteroid. Two inhalations twice daily

Long-acting selective beta2 agonist with corticosteroid.

Fostair NEXThaler 200/6
• Adult for asthma maintenance therapy: two inhalations twice daily, with a maximum of four inhalations per day.

Fostair NEXThaler 100/6
• Adult for asthma maintenance therapy: one to two inhalations twice daily, with a maximum of four inhalations per day.
• Adult for asthma maintenance and reliever therapy: one inhalations twice daily, with a maximum of eight inhalations per day.
• Adult for COPD with FEV1 <50% predicted: two inhalations twice daily.

Fostair 100/6
• Adult for asthma maintenance therapy: one to two inhalations twice daily, with a maximum of four inhalations per day.
• Adult for asthma maintenance and reliever therapy: one inhalations twice daily, with a maximum of eight inhalations per day.
• Adult for COPD with FEV1 <50% predicted: two inhalations twice daily.

Fostair 200/6
• Adult for asthma maintenance therapy: two inhalations twice daily, with a maximum of four inhalations per day.

Long-acting selective beta2 agonist with corticosteroid.

Fusacomb 50/250 Easyhaler
• 12 years and over for prophylaxis of asthma: one inhalation twice daily and can be reduced to once daily.
Fusacomb 50/500 Easyhaler
• 12 years and over for prophylaxis of asthma: one inhalation twice daily.
• Adult for COPD: one inhalation twice daily.

The GCE Zen-O portable oxygen concentrator is designed to enable patients with respiratory disorders to better manage their oxygen therapy.

Weighing just 4.66 kg the Zen-O can deliver up to 2l/ minute of oxygen in either pulse or continuous flow and is supplied with variety of accessories, including a carry bag and a pull cart for increased mobility.

Zen-O is designed with easy-to-replace sieve bed. The sieve bed can be replaced in the field using simple tools in under five minutes, saving time and money. Zen-O is manufactured in the UK.

Zen-O portable oxygen concentrator can deliver up to 2 litres of oxygen in either pulse or
continuous flow.

Stockists: The Oxygen Store, Intermedical Homecare.

Antimuscarinic bronchodilator.

For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.

For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.

Antimuscarinic bronchodilator.

In the case of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 micrograms every 4 hours and when required, hourly use is occasionally necessary.

In the case of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.

Antimuscarinic bronchodilator.

For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.

For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.

Antimuscarinic bronchodilator.

For the treatment of excessive respiratory secretions in palliative care by subcutaneous injection
Adult: 200 mcg every 4 hours and when required, hourly use is occasionally necessary, particularly in excessive respiratory secretions.

For the treatment of excessive respiratory secretions in palliative care by subcutaneous infusion
Adult: 0.6–1.2 mg/24 hours.